#United States Liquid Biopsy Market

[aarunresearcher]

United States liquid biopsy market size reached USD 563.6 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,775.8 Million by 2033, exhibiting a growth rate (CAGR) of 13.6% during 2025-2033. The rising need for personalized treatments among individuals across the country is propelling the adoption of this method to analyze the genetic mutations in an efficient manner, which is primarily driving the market growth.

[healthcaremarketanalysis]

Liquid Biopsy Market: Trends, Growth Opportunities, and Future Insights

The liquid biopsy market is expanding rapidly, driven by advancements in precision medicine, non-invasive diagnostic methods, and growing demand for early cancer detection. This technology, which allows doctors to detect cancer and other diseases through blood samples instead of invasive tissue biopsies, is revolutionizing patient care by offering faster, less painful, and more accessible testing options. In this blog, we’ll explore the key trends, market drivers, growth opportunities, and challenges shaping the liquid biopsy industry.

Download PDF Brochure

What is a Liquid Biopsy?

A liquid biopsy is a non-invasive diagnostic test that detects genetic mutations, cancer markers, or other biomarkers in blood, urine, saliva, or other bodily fluids. Unlike traditional biopsies, which require tissue samples through surgery, liquid biopsies provide valuable information about a patient’s condition using small samples, significantly reducing discomfort and recovery time. Liquid biopsies can track a tumor’s progress, identify mutations, and monitor response to treatments, which is particularly useful for conditions that are difficult to monitor through tissue biopsies alone.

Key Drivers of Growth in the Liquid Biopsy Market

The liquid biopsy market is experiencing a surge in growth due to several factors:

1. Rising Incidence of Cancer and Demand for Non-Invasive Diagnostics

Cancer remains one of the leading causes of death worldwide, driving demand for diagnostic tools that can detect it early and with minimal invasiveness. Liquid biopsies provide a way to diagnose and monitor cancer by identifying specific biomarkers in the blood, offering a safer and less invasive alternative to surgical biopsies. This demand is particularly high in regions where the aging population and incidence of cancer are on the rise, such as North America and Europe.

2. Advances in Genomics and Precision Medicine

Advances in genomics and the trend toward precision medicine are pushing the liquid biopsy market forward. As genomic research reveals more about the genetic markers associated with diseases, liquid biopsy technologies are becoming more capable of identifying and monitoring these markers. This enables doctors to tailor treatments to individual patients based on their unique genetic profiles, resulting in more effective and personalized treatment plans.

3. Government Funding and Research Investments

Governments and research institutions are investing in cancer research and diagnostics, increasing funding for technologies that can advance early cancer detection. Many health agencies worldwide, such as the National Institutes of Health (NIH) in the United States, are allocating funds to support the development of non-invasive diagnostic tools, fostering innovation and accelerating the growth of the liquid biopsy market.

4. Growth in Companion Diagnostics

Companion diagnostics are tests that help assess a patient’s likelihood of responding to a specific treatment. These diagnostics are particularly important for cancer patients, as liquid biopsies can identify biomarkers that reveal how a patient might respond to certain therapies. This insight is invaluable in oncology, as it can guide treatment decisions and improve patient outcomes, further driving demand for liquid biopsy solutions.

Emerging Applications and Technologies

The scope of liquid biopsy applications is expanding beyond cancer diagnosis. New technologies are unlocking additional uses in areas such as:

1. Infectious Disease Monitoring

Liquid biopsies can detect circulating pathogens in the bloodstream, opening the possibility of diagnosing and monitoring infectious diseases like HIV, tuberculosis, and hepatitis. This potential is particularly valuable in areas with high rates of these infections, where liquid biopsies could improve diagnosis and treatment tracking in real time.

2. Cardiovascular Disease Detection

Research is exploring the use of liquid biopsies to identify cardiovascular biomarkers, which could assist in early diagnosis and monitoring of heart disease. By detecting certain genetic markers and proteins in the blood, liquid biopsy technology could help predict cardiovascular events, enabling preventive measures and more targeted therapies.

3. Neurological Conditions

Although still in early stages, liquid biopsy applications in neurology could revolutionize the diagnosis and monitoring of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. By detecting biomarkers associated with brain conditions, liquid biopsies offer a non-invasive way to diagnose neurological conditions earlier than traditional imaging techniques allow.

Competitive Landscape and Key Players

The liquid biopsy market is highly competitive, with several established companies and new entrants working to advance the technology. Key players include:

Guardant Health: Known for its Guardant360 test, which screens for cancer mutations in the blood. Guardant Health focuses on developing liquid biopsy tests for advanced-stage cancers and companion diagnostics.

Biocept: Specializes in liquid biopsy tests for both solid tumor cancers and brain metastases, with a focus on molecular diagnostics.

Foundation Medicine: Known for its FoundationOne Liquid test, which provides genomic profiling to inform cancer treatment decisions.

Natera: A leader in reproductive health diagnostics, Natera also offers liquid biopsy tests for oncology, including its Signatera test, which is used for minimal residual disease detection and monitoring.

GRAIL: Recently acquired by Illumina, GRAIL is focused on developing multi-cancer early detection tests using its proprietary liquid biopsy technology.

These companies are investing heavily in R&D, aiming to improve the accuracy, affordability, and applicability of liquid biopsies across a range of diseases.

Market Challenges

Despite its advantages, the liquid biopsy market faces several challenges:

1. Technical Limitations

Detecting circulating tumor DNA (ctDNA) and other biomarkers in blood samples is complex and requires advanced technology. While some cancers shed more ctDNA, making detection easier, others do not, which can limit the effectiveness of liquid biopsies in certain cases.

2. Regulatory and Reimbursement Hurdles

In many regions, liquid biopsy tests face stringent regulatory requirements and approval processes. Additionally, the cost of these tests and limited reimbursement options can restrict their accessibility for patients, particularly in lower-income regions or for those without sufficient healthcare coverage.

3. Data Interpretation and False Positives

Interpreting data from liquid biopsies is complex, and there is a risk of false positives, where benign mutations or low levels of ctDNA are detected as indicators of cancer. This challenge emphasizes the need for high accuracy and specificity in liquid biopsy technology to ensure reliable results.

Future Outlook and Growth Opportunities

The liquid biopsy market is expected to continue its upward trajectory, driven by technological advancements and broader applications. Key growth areas include:

1. Artificial Intelligence Integration

AI and machine learning algorithms are being integrated into liquid biopsy analysis, enhancing the accuracy of biomarker detection and interpretation. By automating complex data analysis, AI could reduce false positives and help refine liquid biopsy results, making them more reliable and accessible.

2. Expanding Beyond Oncology

While cancer detection remains the primary application, there is substantial potential for liquid biopsies in infectious disease, cardiovascular health, and neurology. The expansion into these areas could open new revenue streams for companies and significantly broaden the market’s scope.

3. Global Market Expansion

Emerging markets, particularly in Asia-Pacific and Latin America, offer high growth potential for the liquid biopsy market. Government initiatives, growing healthcare infrastructure, and a rising prevalence of cancer and other diseases are driving demand in these regions, presenting opportunities for companies to expand their global footprint.

Conclusion

The liquid biopsy market is at the forefront of a healthcare revolution, offering a less invasive, faster, and more precise way to detect and monitor diseases. With applications expanding beyond oncology, new technologies like AI integration, and increasing demand for non-invasive diagnostics, the liquid biopsy market holds immense potential for growth. As the industry continues to innovate, companies that leverage these advancements will not only drive the market forward but also play a pivotal role in shaping the future of personalized and preventive healthcare.

[bhushans]

Meeting the Needs of a Growing Population: The Evolving Global Liquid Biopsy Market

The global liquid biopsy market is positioned for rapid expansion, with an estimated revenue of USD 1,538.3 million in 2023. According to insights from healthcare domain experts, providers in the liquid biopsy sector can anticipate a robust Compound Annual Growth Rate (CAGR) of 21.7% through 2033. By the end of the forecast period, the market is projected to achieve a valuation of USD 10,938.6 million, reflecting significant growth opportunities within the healthcare industry.

Liquid biopsy, a non-invasive diagnostic technique that detects biomarkers and genetic material in bodily fluids, is revolutionizing cancer diagnosis, monitoring, and treatment. This innovative approach offers several advantages over traditional tissue biopsy, including real-time monitoring, early detection of treatment response or resistance, and the ability to capture tumor heterogeneity

Tumor tissue is currently the gold standard for determining the kind and stage of cancer. Important players are attempting to reduce the current obstacles to its utilization in order to increase its potential applications in the future. The feasibility of liquid biopsy techniques for identifying cancer patients’ genetic profiles has also been shown by a number of research. The studies carefully take into account the reactions in order to track the course of treatment and identify any early warning symptoms of therapeutic resistance.

Request Your Detailed Report Sample With Your Work Email : https://www.futuremarketinsights.com/reports/sample/rep-gb-1396

Liquid biopsies have become more common in recent years due to the desire for more personalized treatment options. Since liquid biopsy is widely available and reasonably priced in many labs, particularly in developing countries, its use is growing in popularity. For instance, several labs offer liquid biopsy tests.

“Key players are bringing cost reductions in liquid biopsy tests and partnering with local product distributors to strengthen their network base in target markets. Currently, a trend toward emerging economies has been spotted, as cancer cases are particularly on the rise, and a large population base provides significant opportunities in these markets,” says an FMI analyst.

Key Takeaways from the Liquid Biopsy Market Report

The North America liquid biopsy market is expected to account for a leading share of 50.84%. The United States is predicted to account for 43.8%, enjoying a dominant share in the global and regional markets.

The Europe market is anticipated to acquire a market share of 19.6% in 2023. Germany holds a prominent share in the region. In 2023, the country is predicted to amass a total of 6.6% share in the global market.

In Europe, the United Kingdom is predicted to expand at a robust CAGR of 26.4% through 2033.

In Asia Pacific, China and India display a remarkable percentage of growth, i.e., 29.7% and 24.4%, respectively, through 2033.

CTC (Circulating Tumor Cells) is projected to obtain a significant market share of 56.9% by biomarker type in 2023.

By sample type, blood sample type holds prominence in the liquid biopsy market.

Key Developments by Liquid Biopsy Market Players

QIAGEN N.V. (the Netherlands), in May 2022, introduced a therascreen EGFR Plus RGQ PCR Kit, which is a new in vitro diagnostic test for the analysis of sensitive EGFR mutation.

Guardant Health, Inc., in June 2021, introduced Guardant360 Response test that finds variations in circulating tumor DNA (ctDNA) levels.

Hoffmann-La Roche Ltd. (Switzerland), in October 2020, gained United States FDA approval for the extended claims for cobas EGFR Mutation Test v2 to be deployed as a companion diagnostic for an extensive range of therapies to manage non-small cell lung cancer (NSCLC).

Biocept, Inc., in March 2020, agreed with a California-based Independent Physician Association (IPA) to offer its Target Selector liquid assay services to patients and physicians in the network.

Key Companies Profiled:

BIOCEPT, INC.

Qiagen N.V.

Trovagene, Inc

Janssen Global Services, LLC

MDxHealth SA

Natera, Inc

F. Hoffmann-La Roche Ltd

Silicon Biosystems

Pathway Genomics Corporation

Sysmex Corporation

Others

Key Segments Profiled in the Liquid Biopsy Industry Survey:

By Biomarker Type:

CTCs (Circulating Tumour Cells)

ctNA (Circulating tumor Nucleic Acids)

Exosomes

By Sample Type:

Blood Liquid Biopsy

Urine Liquid Biopsy

Other (Plasma, Saliva, CSF) Liquid Biopsy

By Application Type:

Liquid Biopsy for Lung Cancer

Liquid Biopsy for Gastrointestinal Cancer

Liquid Biopsy for Prostate Cancer

Liquid Biopsy for Breast Cancer

Liquid Biopsy for Colorectal Cancer

Liquid Biopsy for Leukemia

By Region:

North America

Latin America

Western Europe

Eastern Europe

Asia Pacific Excluding Japan

Japan

Middle East and Africa

[b2bbusiness]

Advancements and Market Trends in Colorectal Cancer Treatment

Colorectal cancer, a type of cancer that starts in the colon or rectum, is one of the most prevalent and deadly cancers worldwide. Despite significant progress in early detection and treatment options, colorectal cancer remains a significant health challenge, driving ongoing research, innovation, and investment in the market. This article explores the current landscape of the colorectal cancer market, including recent advancements, emerging trends, and future prospects.

Market Overview: The global colorectal cancer market has experienced steady growth in recent years, driven by factors such as the rising incidence of colorectal cancer, an aging population, and advancements in treatment options. According to the American Cancer Society, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States, highlighting the significant market potential for colorectal cancer treatments.

Key Players: Several pharmaceutical companies and biotech firms are actively involved in the development and commercialization of colorectal cancer therapies. Key players in the market include:

Roche Holding AG: Roche's blockbuster drug, Avastin (bevacizumab), is widely used in the treatment of colorectal cancer, particularly in combination with chemotherapy.

Merck & Co., Inc.: Merck's immunotherapy drug, Keytruda (pembrolizumab), has shown promising results in treating advanced colorectal cancer with specific genetic mutations.

Bayer AG: Bayer's Stivarga (regorafenib) is approved for the treatment of metastatic colorectal cancer that has progressed after standard therapies.

Bristol Myers Squibb: Bristol Myers Squibb's Opdivo (nivolumab) is another immunotherapy option being explored for the treatment of colorectal cancer.

Pfizer Inc.: Pfizer's Xalkori (crizotinib) and Lorbrena (lorlatinib) are among the targeted therapies being investigated for colorectal cancer treatment.

Recent Advancements: The colorectal cancer market has witnessed several significant advancements in recent years, driving improvements in patient outcomes and treatment efficacy. These advancements include:

Immunotherapy: Immunotherapy has emerged as a promising approach for colorectal cancer treatment, particularly in patients with specific genetic mutations or microsatellite instability-high (MSI-H) tumors. Drugs like Keytruda and Opdivo harness the body's immune system to target and destroy cancer cells.

Targeted Therapies: Targeted therapies, which specifically target cancer cells based on their genetic makeup, have shown efficacy in colorectal cancer treatment. Drugs like Stivarga and Xalkori inhibit specific molecular pathways involved in cancer growth and progression.

Biomarker Testing: Advances in biomarker testing have enabled oncologists to personalize treatment approaches based on the unique genetic profile of each patient's tumor. Biomarker testing helps identify patients who are most likely to benefit from targeted therapies or immunotherapy.

Minimally Invasive Surgery: Minimally invasive surgical techniques, such as laparoscopic and robotic-assisted surgeries, have become standard in the treatment of colorectal cancer. These techniques offer faster recovery times, reduced postoperative pain, and improved cosmetic outcomes compared to traditional open surgery.

Emerging Trends: Several emerging trends are shaping the future of the colorectal cancer market:

Combination Therapies: Researchers are exploring the potential benefits of combining immunotherapy with other treatment modalities, such as chemotherapy, targeted therapy, and radiation therapy, to enhance treatment efficacy and overcome resistance mechanisms.

Liquid Biopsies: Liquid biopsy techniques, which involve analyzing tumor-derived genetic material in blood samples, hold promise for early detection, monitoring treatment response, and detecting the emergence of resistance mutations in colorectal cancer patients.

Artificial Intelligence (AI) and Machine Learning: AI and machine learning algorithms are being increasingly utilized to analyze complex genomic and imaging data, predict treatment outcomes, and identify novel therapeutic targets in colorectal cancer.

Patient-Centric Care: There is a growing emphasis on patient-centered care in the management of colorectal cancer, with healthcare providers focusing on improving patient education, support services, and survivorship care to enhance overall quality of life.

For more insights into the Colorectal Cancer market forecast, download a free report sample

[isayresearchblog]

Multi Cancer Early Detection Market Size, In-Depth Assessment, CAGR, Demand, and Opportunity Analysis 2032

The Multi Cancer Early Detection Market market size study shifts its attention to in-depth business challenges, defined investment opportunities, market share coupled with product type and applications, key companies responsible for the production, and upcoming market opportunities.

According to our latest research, the global Multi Cancer Early Detection Market size is estimated to be 2.44 Billion by 2032 from USD 0.83 Billion in 2022, with a change of 14.15% between 2023 and 2032.

The report aims to offer a comprehensive analysis on the global Multi Cancer Early Detection market. It concentrates on the market dynamics, technological inclinations, and understandings on different end-user industries and product types. Additionally, it examines the key players and the competitive landscape in the global Multi Cancer Early Detection market.

Get Free Exclusive Sample of this Premium Report at: https://isayresearch.com/sample/2295

The Global Multi Cancer Early Detection Market analysis report is the outcome of incessant efforts guided by knowledgeable forecasters, innovative analysts and brilliant researchers. With the specific and state-of-the-art information provided in this report, businesses can get idea about the types of consumers, consumer’s demands and preferences, their perspectives about the product, their buying intentions, their response to particular product, and their varying tastes about the specific product which is already present in the market. By providing an absolute overview of the market, Multi Cancer Early Detection Market report covers various aspects of market analysis, product definition, market segmentation, key developments, and the existing vendor landscape.

List of Prominent Players:

Grail, LLC (Illumina, Inc.)

Exact Sciences Corporation.

Foundation Medicine, Inc.

AnchorDx

Guardant Health, Inc.

Burning Rock Biotech Limited

GENECAST

Laboratory for Advanced Medicine, Inc.

Singlera Genomics Inc.

Others

Segmentation of Global Multi Cancer Early Detection Market:

By Type:

Liquid Biopsy

Gene Panel, LDT & Others

By End-Use:

Hopsitals

Diagnostic Laboratories

Others

Market segment by Region, regional analysis covers

North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, Spain, Rest of Europe)

Asia Pacific (China, Japan, India, Southeast Asia, Rest of APAC)

Latin America (Brazil, Argentina, Rest of Latin America)

Middle East & Africa (GCC Countries, UAE, Rest of MEA)

Report Target Clients:

Investors and Private Equity Firms

Multi Cancer Early Detection Providers

Suppliers as well as Distributors

Government and Regulatory Agencies

Read Summary Of the report @ https://isayresearch.com/report/2295/multi-cancer-early-detection-market/

Read Insights For Your Business

Company Profile

iSay Research is the leading research company offering both tactical and strategic support to all our customers. Customer satisfaction is our goal and that is why, we have a team of skilled and experienced specialist with the ability to do data mining, information management, and revenue enhancement solutions to ensure that our clients make informed decisions when coming to investing in the market.

Contact

iSay Solutions LLC

166 Geary St. 15th Floor Suite #212, 

San Francisco, California 94108, 

United States

Tel: +14156709191

Email: support@isayresearch.com

[helthcareheven]

ReVitalMed: Pioneering Single-Use Medical Device Regeneration

Introduction to Single Use Devices Single-use medical devices (SUDs) are designed and labeled by their manufacturers to be discarded after one use on a single patient. Common types of SUDs include biopsy forceps, cardiac catheters, drug-eluting stents, and surgical instruments. SUDs offer convenience for healthcare facilities by eliminating cleaning, disinfection, sterilization, and repair costs associated with reusable devices. However, SUDs also generate a significant amount of medical waste.

The Process of Reprocessing SUDs Some healthcare facilities have begun reprocessing select SUDs to reduce costs and waste. The reprocessing of SUDs involves cleaning, disinfection, sterilization, inspection, and repackaging to prepare a used device for another procedure. The main steps in reprocessing SUDs are:

Cleaning Thorough cleaning is the first and most important step to remove contaminants from the last clinical use. Robotic, ultrasonic, and manual cleaning methods are used with soap solutions to flush out all residues from lumens and crevices of devices.

Disinfection After cleaning, high-level disinfection using liquid chemicals like peracetic acid or hydrogen peroxide vapor helps eliminate infectious pathogens and microbes. Strict adherence to disinfectant contact times is necessary for effectiveness.

Inspection and Function Testing Reprocessed devices then undergo 100% visual, optical, and electronic inspection using magnifying tools. Functionality of moving parts, electrical components, and material integrity are evaluated to prevent failures.

Sterilization Steam sterilization in an autoclave is the standard method to sterilize heat-stable reprocessed SUDs. Other techniques like ethylene oxide gas or plasma sterilization can be used as well if validated.

Repackaging and Labeling Once sterilized, devices are individually wrapped or placed in dedicated trays with internal sterilization indicators. Clear labeling denotes the device as reprocessed. Quality control records trace each device back to its original manufacturer.

Regulatory Considerations around SUD Reprocessing The reprocessing of SUDs raises concerns from a regulatory perspective:

Lack of Manufacturer Validation Original equipment manufacturers did not design or validate SUDs to withstand multiple uses, high-temperature sterilization, or cleaning chemicals. Significant post-market validation is required.

Liability and Safety Issues If a reprocessed device malfunctions or causes harm, liability is difficult to determine between the reprocessor and original manufacturer. Safety and performance could be compromised without oversight.

Regulatory Approval Requirements In many countries like the United States, reprocessors must obtain 510(k) marketing clearance from regulators like the FDA before commercially distributing reprocessed SUDs. However, regulations are still evolving.

Cost-Effectiveness Analysis While initial reprocessing costs can be high, long-term savings from avoiding purchase of new SUDs can offset cleaning and sterilization fees—especially for high-cost devices. Reliability and remaining useful life need evaluation.

Adoption Challenges in Healthcare Systems Changing standards of care and ingrained clinical preferences favor single-use over reprocessed devices. Reprocessors must demonstrate comparable quality and safety to gain broader acceptance.

The Future of SUD Reprocessing As healthcare costs continue rising, SUD reprocessing offers a means to improve sustainability and access to care. However, unresolved concerns around validation, quality assurance, and regulator oversight could slow further development. Standardized best practices, comprehensive regulations, and robust post-market surveillance may encourage more healthcare providers and patients to embrace this option in the future. With appropriate safeguards and diligence by all stakeholders, reprocessing select SUDs shows promise as a practical solution to reduce medical waste and contain costs from expensive disposable technologies.

[marketdevelopment]

Liquid Biopsy Market Latest Innovations, Drivers and Industry Status 2023 to 2030

The Global Liquid Biopsy Market size is expected to grow from USD 1.59 billion in 2022 to USD 7.02 billion by 2030, at a CAGR of 20.4% during the forecast period (2023-2030).

A liquid biopsy is a minimally invasive diagnostic procedure that involves analyzing various biomarkers (such as circulating tumor cells, cell-free DNA, exosomes, and other nucleic acids) found in bodily fluids like blood, urine, or saliva. It's primarily used for the detection and monitoring of diseases, particularly cancer.

Advances in technologies such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and digital PCR have greatly enhanced the sensitivity and specificity of liquid biopsy tests, enabling more accurate detection and monitoring of diseases.

Liquid biopsies have gained particular attention in the field of oncology for early cancer detection, monitoring treatment response, and detecting resistance mutations. They offer a non-invasive alternative to tissue biopsies and can provide real-time information on tumor dynamics.

While oncology remains the primary focus of liquid biopsy applications, researchers and companies have been exploring its potential in other areas such as prenatal testing, infectious disease diagnostics, transplant monitoring, and autoimmune disease detection.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @

https://introspectivemarketresearch.com/request/16300

Updated Version 2024 is available our Sample Report May Includes the:

Scope For 2024

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (structure of the report)

Research methodology adopted by Worldwide Market Reports

Leading players involved in the Liquid Biopsy Market include:

Agilent Technologies (United States), Bio-Rad Laboratories, Inc. (United States), Beckman Coulter(United States), Illumina (United States), PerkinElmer (United States), Becton, Dickinson and Company (BD) (United States), Johnson & Johnson (United States), Abbott Laboratories (United States), Cancer Genetics, Inc. (United States), Myriad Genetics, Inc. (United States) 

Moreover, the report includes significant chapters such as Patent Analysis, Regulatory Framework, Technology Roadmap, BCG Matrix, Heat Map Analysis, Price Trend Analysis, and Investment Analysis which help to understand the market direction and movement in the current and upcoming years. 

If You Have Any Query Liquid Biopsy Market Report, Visit:

https://introspectivemarketresearch.com/inquiry/16300

Segmentation of Liquid Biopsy Market:

By Cancer Type

Lung

Breast

Liver

By Circulating Biomarker

Circulating Tumor DNA

Circulating Tumor Cells

By End-User

Hospitals

Laboratories

Government Research Centre

By Regions: -

North America (US, Canada, Mexico)

Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)

Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)

Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)

Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)

South America (Brazil, Argentina, Rest of SA)

Key Reasons To Invest In Liquid Biopsy Market Report:

To provide a complete structure and a basic overview of the Liquid Biopsy market.

To provide insights into important Liquid Biopsy aspects such as growth trajectory, CAGR value, market share, and revenue analysis.

Assess growth opportunities, threats, market drivers, and associated risks.

To understand the Liquid Biopsy market competition by analysing the top business people along with market profiles, import/export details, revenue, profit, and market shares.

Indicate pricing structure, import/export details, supply chain analysis, SWOT analysis to facilitate key decision-making process.

Analysing emerging Liquid Biopsy market segments and sub-segments to drive ultimate growth, investment analysis, and future growth opportunities.

Understand sources of knowledge, intended research methodology, and important conclusions.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Acquire This Reports: -

https://introspectivemarketresearch.com/checkout/?user=1&_sid=16300

About us:

Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to assisting our clients to grow and have a successful impact on the market. Our team at IMR is ready to assist our clients to flourish their business by offering strategies to gain success and monopoly in their respective fields. We are a global market research company, that specializes in using big data and advanced analytics to show the bigger picture of the market trends. We help our clients to think differently and build better tomorrow for all of us. We are a technology-driven research company, we analyse extremely large sets of data to discover deeper insights and provide conclusive consulting. We not only provide intelligence solutions, but we help our clients in how they can achieve their goals.

Contact us:

Introspective Market Research

3001 S King Drive,

Chicago, Illinois

60616 USA

Ph no: +1-773-382-1047

Email: sales@introspectivemarketresearch.com

[blueweave]

North America Cancer Biopsy Market size at USD 10.34 Billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects the North America Cancer Biopsy Market size to expand at a CAGR of 9.77% reaching a value of USD 22.87 Billion by 2030. The market is expected to grow significantly due to the high burden of cancer among the population, with a large number of breast, colon, and rectal cancer cases, particularly in the United States and Canada. Initiatives undertaken by the government for the early diagnosis of cancer are also driving market growth such as The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides free and low-cost breast and cervical cancer screening services for people who can’t afford them. Moreover, the market is being driven by technological advancements and product launches by key players. For example, the launch of new oncology liquid biopsy products is contributing to market growth.

Opportunity: Collaborations and Partnerships

Collaborations and partnerships represent a pivotal opportunity in the North America Cancer Biopsy Market. The complex landscape of cancer diagnostics and biopsy technologies necessitates strategic alliances between key players, research institutions, and healthcare organizations. By fostering collaborations, stakeholders can leverage combined expertise, resources, and innovative technologies to accelerate advancements in cancer biopsy methodologies. These partnerships facilitate the development of cutting-edge diagnostic tools, enhance research capabilities, and promote the efficient implementation of novel biopsy techniques. For instance, SOPHiA GENETICS, a cloud-native software firm in the healthcare market, has entered into an agreement with Memorial Sloan Kettering Cancer Centre (MSK) to give physicians and researchers new tools to improve their testing and analytical capabilities. This includes using patented complete Genomic Panel (CGP) sequencing assays like MSK-ACCESS®, which will be commercialized by SOPHiA GENETICS as the first complete ctDNA liquid biopsy test powered by the SOPHiA DDMTM Platform. Furthermore, collaborative efforts create synergies that can streamline regulatory processes, ensuring quicker market access for innovative biopsy solutions. Overall, collaborations and partnerships emerge as a key avenue for fostering innovation, addressing unmet needs, and driving the growth of the North America Cancer Biopsy Market.

Impact of Geopolitical Tensions on the North America Cancer Biopsy Market

Geopolitical tensions can impact the North America cancer biopsy market in various ways. The increasing conflicts may disrupt the overall market dynamics, leading to uncertainties in trade and investment. Cross-border capital outflows triggered by rising geopolitical tensions could pose a threat to macro-financial stability, affecting the financial landscape within the region. These uncertainties may influence decision-making processes, leading to delays or fluctuations in healthcare investments, research, and technology adoption in the field of cancer diagnostics. As geopolitical challenges evolve, businesses operating in the North America Cancer Diagnostics Market need to navigate through this landscape strategically to ensure sustained growth and stability.

Sample Request @ https://www.blueweaveconsulting.com/report/north-america-cancer-biopsy-market/report-sample

[informationtechnology0101]

Revolutionizing the Ovarian Cancer Market: Strategies for Success | DLI

Ovarian Cancer Overview:

Ovarian Cancer is a formidable health challenge affecting women globally. It is characterized by the abnormal growth of cells in the ovaries, which are vital components of the female reproductive system. Often diagnosed at an advanced stage, ovarian cancer poses significant clinical and therapeutic complexities.

Ovarian cancer silently appears as a powerful foe that demands undivided attention. It is unyielding and resilient. It affects women of all ages and socioeconomic backgrounds and spares no one. This sneaky illness hides its presence, frequently coming to light only when the fight grows more difficult.

The Market Competitors Listed Below are Revolutionizing Healthcare with Innovative Diagnostic Inventions:

Price & Market Access

Diagnostic Analysis:

Early Detection Challenges:

Early diagnosis of ovarian cancer remains a critical issue due to its asymptomatic nature in the initial stages. Lack of specific symptoms and effective screening tools makes timely detection a formidable task.

Screening Methods:

Currently, screening methods primarily include pelvic examinations, transvaginal ultrasounds, and blood tests measuring CA-125 levels. However, these methods often lack the sensitivity and specificity needed for reliable early detection.

Treatment Analysis:

Standard Treatment Modalities:

Treatment approaches for ovarian cancer encompass a multidisciplinary approach, including surgery, chemotherapy, radiation therapy, and targeted therapy. The extent of surgical intervention and choice of chemotherapeutic agents are determined by factors like stage, histology, and patient's overall health.

Emerging Therapies:

Immunotherapy and personalized medicine are emerging as promising avenues in ovarian cancer treatment. These approaches aim to enhance the body's natural immune response and tailor treatments based on the genetic profile of the tumor.

Regulatory Framework:

FDA and EMA Guidelines:

Regulatory bodies like the FDA (Food and Drug Administration) in the United States and EMA (European Medicines Agency) in Europe play a pivotal role in approving and regulating treatments for ovarian cancer. Rigorous clinical trials and safety assessments are mandatory before a therapy can be marketed.

Therapeutics:

Targeted Therapies:

Targeted therapies like PARP inhibitors and angiogenesis inhibitors have shown promise in treating specific types of ovarian cancer. They work by interfering with the specific molecular pathways that cancer cells rely on for growth.

Immunotherapies:

Immunotherapies, including checkpoint inhibitors, are being investigated for their potential to enhance the body's immune system to recognize and attack ovarian cancer cells.

Diagnostic Techniques:

Genomic Profiling:

Advancements in genomic profiling have revolutionized the understanding of ovarian cancer. DNA sequencing and molecular profiling enable a more precise characterization of the tumor, guiding treatment decisions.

Liquid Biopsies:

Liquid biopsies, analyzing blood or other bodily fluids, offer a non-invasive method to monitor tumor genetics and detect minimal residual disease.

Treatment Techniques:

Minimally Invasive Surgery:

Minimally invasive techniques, such as laparoscopy, have gained prominence in ovarian cancer surgery. They offer shorter recovery times and reduced post-operative complications.

Hyperthermic Intraperitoneal Chemotherapy (HIPEC):

HIPEC is an innovative technique that delivers heated chemotherapy directly to the abdominal cavity during surgery. This approach targets residual cancer cells and has shown promise in improving survival rates.

Browse More Information:

Clinical Assessment:

Multidisciplinary Teams:

Ovarian cancer treatment requires collaboration among various specialists, including gynecologic oncologists, surgeons, medical oncologists, and radiologists, to create personalized treatment plans.

Survivorship Care:

Long-term survivorship care plans are essential to address the physical, emotional, and psychological aspects of recovery after ovarian cancer treatment.

Expanding Therapeutic Landscape:

The ovarian cancer therapeutics market is witnessing a surge in research and development efforts, with a growing number of targeted and immunotherapeutic agents in the pipeline.

Regional Research Initiatives:

Different regions are contributing to ovarian cancer research with unique perspectives and approaches, fostering a global network of knowledge-sharing and collaboration.

Conclusion:

Ovarian cancer poses significant clinical challenges, but with advances in diagnostics, treatment modalities, and regulatory frameworks, there is hope for improved outcomes and a brighter future for those affected by this disease.

Browse Through More Oncology Diseases Research Reports.

Related Reports:

Diverticulitis: A Complete Guide to the Symptoms, Causes, and Treatments

When it comes to strategic Diabetes Disease consultancy, some of the areas we assist you understand include Regulatory Insights, Disease Landscape, and Market Access Expertise.

Find treatments for HPV illness using specialized market entry strategies. FDA/EMA insights and clinical trial advice. Examine right away!

Learn about specific approaches to Pancreatic Cancer Disease market access, pricing, and reimbursement. Learn about market research and clinical trials. Change your business immediately.

Learn about KOLs, the FDA, epidemiology, price reimbursement, and more in this market report on Anemia Disease. Your trustworthy source for info on anemia. Examine right away!

[poojascmi]

Global Cancer Diagnostics Market Is Estimated To Witness High Growth Owing To Increasing Demand for Early Cancer Detection

The global Cancer Diagnostics market is estimated to be valued at US$ 59.1 billion in 2023 and is expected to exhibit a CAGR of 9.6% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. A) Market Overview: The Cancer Diagnostics market includes various diagnostic tools and techniques used for the early detection, diagnosis, and management of cancer. These diagnostics play a crucial role in determining the type, stage, and treatment plan for cancer patients. The market offers a wide range of products such as antibodies, biomarkers, imaging modalities, and molecular tests. The increasing prevalence of cancer and the need for early detection are driving the demand for cancer diagnostics. These diagnostics provide numerous advantages, including precise diagnosis, targeted therapies, and personalized treatment plans, ultimately improving patient outcomes. B) Market key trends: One key trend shaping the Cancer Diagnostics market is the growing emphasis on liquid biopsies. Liquid biopsies refer to the non-invasive testing of tumor biomarkers from bodily fluids such as blood or urine. They offer several advantages over traditional tissue biopsies, including the ability to monitor cancer progression and treatment response in real-time. Liquid biopsies also enable early detection of cancer recurrence and minimal invasiveness for patients. For example, companies like Natera, Inc. have developed liquid biopsy tests, such as Signatera, which can detect minimal residual disease in colorectal cancer patients with high sensitivity. C) PEST Analysis: - Political: Governments worldwide are focusing on implementing cancer control programs and increasing funding for cancer research. This political support is driving the growth of the Cancer Diagnostics market. For instance, the National Cancer Moonshot Initiative in the United States aims to accelerate progress in cancer prevention, diagnosis, and treatment. - Economic: The rising healthcare expenditure and growing disposable income of individuals are fueling the demand for advanced cancer diagnostics. Additionally, the cost-effectiveness of these diagnostics in terms of improved patient outcomes and reduced treatment costs is contributing to market growth. - Social: The increasing awareness about the importance of early cancer detection and the proactive approach towards healthcare are positively influencing the market. Moreover, factors such as lifestyle changes, tobacco consumption, and unhealthy diets are contributing to the rising incidence of cancer. - Technological: Technological advancements in diagnostic techniques, such as next-generation sequencing, liquid biopsies, and companion diagnostics, are driving market growth. These advancements enable earlier detection, better accuracy, and personalized treatment approaches. D) Key Takeaways: Paragraph 1: The Global Cancer Diagnostics Market Size is expected to witness high growth, exhibiting a CAGR of 9.6% over the forecast period. This growth is primarily attributed to increasing demand for early cancer detection. Early diagnosis plays a critical role in improving patient outcomes and reducing the overall burden of cancer. Paragraph 2: Regionally, North America dominates the Cancer Diagnostics market due to factors such as a high prevalence of cancer, well-established healthcare infrastructure, and government initiatives towards cancer control. However, Asia Pacific is expected to witness the fastest growth during the forecast period. The increasing healthcare expenditure, growing awareness about cancer, and improving access to healthcare facilities are driving market growth in this region.

[aarunresearcher]

The United States liquid biopsy market is experiencing rapid growth and significant advancements as a groundbreaking diagnostic tool in the field of cancer detection and monitoring. This minimally invasive technique involves the analysis of blood or other bodily fluids to identify genetic material or biomarkers originating from tumors, presenting a paradigm shift in cancer diagnostics. 

[aartichede08]

Future Of North American Oncology Drugs Market: Size, Share, And Forecast 2019–2028

Cancer research is advancing rapidly and new medicines in development take many innovative approaches to fighting the disease. There has been tremendous innovation over the past decade with the emergence of new drugs with very promising efficacy, such as, immunotherapy, along with increasing adoption of precision medicine technologies including companion diagnostics and targeted therapy, as well as advanced monitoring techniques such as liquid biopsy. New treatment options have become available in the past five years, and the surge of innovation is expected to continue due to a robust pipeline of drugs in clinical development by a large and diverse group of pharmaceutical companies. Over 20 tumour types are being treated with one or more of the 70 new cancer treatments that have been launched over the past five years. Furthermore, the impact of these new medicines on patient care is exemplified by the case of the two PD-1 immuno-oncology drugs, whose rapid uptake reflect their remarkable clinical profile and successive expansion of indications.

To know the scope of our report get a sample on https://www.axiommrc.com/request-for-sample/hc1964-north-american-oncology-drugs-market-report

NORTH AMERICAN ONCOLOGY DRUGS MARKET OUTLOOK

The United States has made significant improvements in cancer care, the death rate from cancer in the US has declined steadily over the past 25 years, according to annual statistics reporting from the American Cancer Society. As of 2016, the cancer death rate for men and women combined had fallen 27% from its peak in 1991. This decline translates to about 1.5% per year and more than 2.6 million deaths avoided between 1991 and 2016, it is attributed by the growing number of drugs and technologies available to patients. The direct costs of cancer represent approximately 5% of total direct US health care expenditures. Besides, very expensive cancer treatments such as the new immunotherapies for cancer are more widely available in America than in countries with national healthcare where there are restrictions based on cost/benefit and budget caps.

Moreover, according to the American Cancer Society, in men, the most common cancers diagnosed are prostate, lung, and colorectal cancers. Together, they account for 42% of all cases in men, with prostate cancer alone accounting for nearly 1 in 5 new cases.

NORTH AMERICAN ONCOLOGY DRUGS MARKET SEGMENTAL OVERVIEW

The report analyses the North America oncology drugs market based on therapeutic modules, cancer type and country.

NORTH AMERICAN ONCOLOGY DRUGS MARKET BY THERAPEUTIC MODULES

Based on the therapeutic modules, the oncology drugs market is segmented into chemotherapy, targeted therapy, immunotherapy, hormonal therapy and others. The other therapeutic modules consist of radiation therapy, stem cell transplant, precision medicine among others. Immunotherapy is expected to dominate the North America market due to its high efficacy and less side effects. Monoclonal antibodies such as trastuzumab, bevacizumab and rituximab are potential immunotherapeutic agents that have achieved magnanimous sales. Moreover, over the past few years, targeted cancer therapies have gained significant attention due to their tumour cell specific action in protecting healthy cells from the toxic effects of oncology drugs.

NORTH AMERICAN ONCOLOGY DRUGS MARKET BY CANCER TYPE

By various cancer types, the North America oncology drugs market is segmented into blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, lung cancer, skin cancer and others. Other cancer types majorly include kidney cancer, head & neck cancers, lip cancer, bladder cancer among others. With rapid population growth and aging, the rising prominence of cancer as a leading cause of death partly reflects marked declines in mortality rates of stroke and coronary heart disease, relative to cancer, in many countries.

NORTH AMERICAN ONCOLOGY DRUGS MARKET BY COUNTRY

Various countries included in the North America oncology drugs market are United States, Canada and Mexico. The United States majorly contributed to the oncology drugs market in 2018. Furthermore, Canada is anticipated to be second largest market in oncology drug market. The U.S. region houses companies engaged in the development of oncology drugs. Additionally, the disposable incomes of consumers and health insurance cover for life-threatening diseases in U.S. are very high which increases the affordability of cancer treatment. In recent years, US Food and Drug Administration (USFDA) has taken initiatives to support the growth of oncology drugs market by providing pre-market approval to the drugs, which are in the clinical phase; thus, accelerating the clinical development.

NORTH AMERICAN ONCOLOGY DRUGS MARKET KEY PLAYERS

North America oncology drugs market is led by companies such as, Roche Holding AG (Switzerland), Amgen Inc. (United States), Takeda Pharmaceutical Company Limited (Japan), Bayer AG (Germany), Boehringer Ingelheim GmbH (Germany), Bristol-Myers Squibb Company (United States), Celgene Corporation (United States), Eli Lilly and Company (United States), Johnson & Johnson (United States), Merck & Co., Inc. (United States), Novartis AG (Switzerland), Pfizer Inc. (United States), Sanofi (France) and Teva Pharmaceutical Industries Limited (Israel). In November 2018, Bristol-Myers Squibb Company the U.S. Food and Drug Administration (FDA) approval of Empliciti (elotuzumab) injection for intravenous use in combination with pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.

Buy now North American Oncology Drugs Market Report https://www.axiommrc.com/buy_now/hc1964-north-american-oncology-drugs-market-report

About Us:

Axiom Market Research & Consulting™ is a full-service market research and data analytics company providing key market intelligence to global companies to take informed business decisions pertaining to their marketing strategy, investments, new product launches, market competition, consumer or end users, social media trends etc. 

Axiom Market Research & Consulting™ offers market research services such as syndicated market research, custom market research, business consulting, and consumer/end user surveys. Under Business to Consumer (B2C) market research offerings, Axiom MRC assists its clients in finding quantitative information/preferences of its brands and services such as, awareness, usages, satisfaction, tracking, ethnicity etc. Axiom MRC offers data collection services through online surveys, social media, data processing and interpretation.

Axiom MRC with its experienced team of research and data analysts, has delivered more than 5000+ Market Research Projects, 3800+ Data Analytics Projects, 1200+ Business Support Projects and has a 800+ Global Client Base. Axiom Market Research & Consulting™ aims to become the preferred market research and data analytics company by providing key market intelligence solutions for client’s business growth.

Contact Us:

Axiom Market Research & Consulting™

3 Germay Dr. Ste 4 - 4666

Wilmington DE 19804

U.S.:- + 1 (845) 875-9786

U.K.:- + 44 (0) 20 3286 9707

Email: sales@axiommrc.com

Website: https://www.axiommrc.com/

Blog: https://industrywatch24.com/

Follow On

LinkedIn: https://www.linkedin.com/company/axiom-market-research-and-consulting/

Twitter:  https://twitter.com/AxiommrcCom

[sueheaven]

Biopsy Needle Market Growing Popularity and Emerging Trends in the Industry Analysis by Key Players

Global Biopsy Needle Market Report from AMA Research highlights deep analysis on market characteristics, sizing, estimates and growth by segmentation, regional breakdowns & country along with competitive landscape, players market shares, and strategies that are key in the market. The exploration provides a 360° view and insights, highlighting major outcomes of the industry. These insights help the business decision-makers to formulate better business plans and make informed decisions to improved profitability. In addition, the study helps venture or private players in understanding the companies in more detail to make better informed decisions. Major Players in This Report Include:

CONMED Corporation (United States)

Medtronic Plc (Ireland)

Olympus (Japan)

Becton, Dickinson and Company (United States)

Boston Scientific Corporation (United States)

Cook Group Incorporated (United States)

Argon Medical Devices, Inc (United States)

INRAD Inc. (United States)

Somatex Medical Technologies (Germany)

Stryker Corporation (United States) Biopsy needle can be defined as a medical instrument used to perform a biopsy, which is a procedure to obtain a sample of cells from your body for laboratory testing. Common needle biopsy procedures include fine-needle aspiration and core needle biopsy. Needle biopsy may be used to take tissue or fluid samples from muscles, bones, and other organs, such as the liver or lungs. Globally, increasing prevalence of cancer and increasing healthcare spending are expected to drive the demand for biopsy needles during the period of study Market Drivers Rising Prevalence of Cancer

Cancer Awareness Initiatives Undertaken By Governments and Global Health Organizations

Increasing Preference for Minimally Invasive Biopsies

Market Trend Emergence of Liquid Biopsy

Opportunities Emerging Economies

Challenges Underdeveloped Healthcare Infrastructure and Dearth of Well-Trained Radiologists and Oncologists

The Biopsy Needle market study is being classified by Application (Tumor, Infection, Inflammation, Others), Working (Fully Automatic, Semi-Automatic), Utility (Disposable Needle, Non Disposable Needle), End User (Hospitals, Clinics, Ambulatory Surgical Centers) Presented By

AMA Research & Media LLP

[techscimarketresearch]

United States Liquid Biopsy Market to be Dominated by Multi-Gene Parallel Analysis Technology till 2027 | TechSci Research

High spending on novel diagnostics technology and Increased focus on early cancer screening are driving the demand for United States liquid biopsy Market in the forecast period, 2023-2027.

According to TechSci Research report, “United States Liquid Biopsy Market By Product & Services (Assay Kits, Instruments, Services), By Circulating Biomarker (Circulating Tumor Cells, Circulating Tumor DNA (ctDNA), Cell-free DNA (cfDNA), Others), By Technology (Multi-gene Parallel Analysis using NGS v/s Single-gene Analysis using PCR Microarrays), By Application (Cancer v/s Non-Cancer), By End User (Hospitals & Clinics, Reference Laboratories, Others), By Region, Competition Forecast & Opportunities, 2027”, the United States liquid biopsy market is expected to grow at an impressive rate during the forecast period, 2023-2027. The adoption of liquid biopsy to tissue biopsy in cancer patients due to its advanced nature featuring fast turnaround time and feasibility and the ability to early cancer screening fuel the demand for liquid biopsies in the United States.

The rise in patient preference for non-invasive treatment procedures and surge in the number of cancer patients are the key driving factors influencing the United States liquid biopsy market in the forecast period. However, the lower sensitivity of some liquid biopsies may restrain the United States liquid biopsy market growth in the forecast period.

Browse over XX market data Figures spread through 70 Pages and an in-depth TOC on "United States Liquid Biopsy Market"

https://www.techsciresearch.com/report/united-states-liquid-biopsy-market/8274.html

The United States liquid biopsy market is segmented into product & services, circulating biomarker, technology, application, end user, regional distribution, and company.

On the basis of the product & services, the United States liquid biopsy market is divided into assay kits, instruments, services. Assay kits are expected to hold the largest market share in the forecast period. The possibility for repeated sampling for liquid biopsy and the ease and affordability is driving the demand for assay kits in the forecast period.

On the basis of the circulating biomarker, the United States liquid biopsy market is divided into circulating tumor cells, circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), and others. Circulating tumor cells accounted for the largest revenue share and are expected to maintain their dominance throughout the forecast period, 2023-2027.

The increasing prevalence of cancer and the advent of ctDNA-based liquid biopsy analysis, which can determine prognosis tumor progression, is driving the market demand. The detection of ctDNA, a potential biomarker for cancer, and the growing demand for non-invasive treatment procedures are bolstering the demand for circulating tumor cells.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=8274

Customers can also request for 10% free customization on this report.

On the basis of the technology, the United States liquid biopsy market is divided into multi-gene parallel analysis using NGS and single-gene analysis using PCR microarrays. Multi-gene parallel analysis using NGS technology is expected to hold the largest market share in the forecast period, 2023-2027.

This technology is highly advanced and can detect several kinds of mutations responsible for tumors, unknown variants, ctDNA mutation detection, and resistive mechanism. Rapid advancements in NGS technology to reduce cost and attain higher accuracy are expected to create lucrative opportunities for the United States liquid biopsy market in the forecast period.

On the basis of the application, the United States liquid biopsy market is divided into cancer and non-cancer. Cancer is expected to account for the largest market share in the forecast period due to the high prevalence of cancer and high-end investments in research to study the implication of liquid biopsy in cancer treatment. These are the key factors influencing the market growth in the forecast period.

On the basis of end user, the United States liquid biopsy market is divided into hospitals & clinics, reference laboratories, and others. Reference laboratories are expected to witness significant growth opportunities in the forecast period. The surge in outsourcing liquid biopsy tests in reference laboratories due to inadequate infrastructure is driving the demand for liquid biopsies in reference laboratories.

Press Release: https://www.techsciresearch.com/news/6909-united-states-liquid-biopsy-market.html

“The availability of a well-developed healthcare system, advanced clinical laboratories, and high demand for advanced instruments and technologies to ease convenience and effectiveness of treatment is driving the demand for the United States liquid biopsy market. The surge in demand for tumor treatment and precision diagnosis and the use of liquid biopsy has opened numerous possibilities for the effective treatment of cancer which is expected to bolster market growth for the forecast period. Also, the growing awareness among patients about the benefits of availing personalized treatment based on drug effect and resistance and the rise in the allocation of funds by the government to upgrade existing healthcare infrastructure is expected to propel the United States liquid biopsy market growth till 2027” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“United States Liquid Biopsy Market By Product & Services (Assay Kits, Instruments, Services), By Circulating Biomarker (Circulating Tumor Cells, Circulating Tumor DNA (ctDNA), Cell-free DNA (cfDNA), Others), By Technology (Multi-gene Parallel Analysis using NGS v/s Single-gene Analysis using PCR Microarrays), By Application (Cancer v/s Non-Cancer), By End User (Hospitals & Clinics, Reference Laboratories, Others), By Region, Competition Forecast &  Opportunities, 2027”, has evaluated the future growth potential of United States liquid biopsy market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United States liquid biopsy market.

Browse Related Reports:

Global Cancer Biopsy Market By Product (Instruments, Kits and Consumables, Services), By Type of Biopsy (Tissue Biopsies (Needle and Surgical Biopsies), Liquid Biopsies, Others), By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Others), By End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers), By Region, Competition Forecast & Opportunities, 2027

https://www.techsciresearch.com/report/cancer-biopsy-market/7399.html

United States Diagnostic Imaging Market By Type (X-Ray Imaging Solutions, Ultrasound Systems, MRI Systems, CT Scanners, Nuclear Imaging Solutions, Mammography, Others), By Mobility (Portable v/s Standalone), By Application (Cardiology, Oncology, Neurology, Orthopedics, Gastroenterology, Gynecology, Others), By End Users (Hospitals & Clinics, Diagnostic Centers, Ambulatory Care Centers, Others), By Region, Forecast & Opportunities, 2027

https://www.techsciresearch.com/report/united-states-diagnostic-imaging-market/4948.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/